Legend’s CD4 CAR-T Trial in TCL is Placed on Clinical Hold by the FDA
Here is a brief preview of this blast: On Tuesday, February 15, Legend announced (press release) that the FDA has placed a clinical hold on LB1901's (LCAR-T2C; autologous CD4 CAR-T) Ph1 trial in r/r TCL. Below, Celltelligence provides insights on plausible causes of the clinical hold and how competitors may achieve a better safety profile.